Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment

International Journal of Antimicrobial Agents

Volumn 34, Issue 6, 2009, Pages 561-565

  Kozai, Seiko ^a   Wada, Tomoyuki ^a   Kida, Tetsuo ^a   Tajika, Tetsuya ^a   Sakaki, Hideyuki ^a   Ohtori, Akira ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Endophthalmitis; Pharmacokinetics pharmacodynamics; Post operative infection; Prophylaxis

Indexed keywords

GATIFLOXACIN;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; ENDOPHTHALMITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SIMULATION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; ENTEROCOCCUS FAECALIS; EYE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; TIME FACTORS;

EID: 70350382723     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.08.002     Document Type: Article

References (26)

1. Wada T., Kozai S., Tajika T., Sakaki H., Suzuki T., and Ohashi Y. Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. J Ocul Pharmacol Ther 24 (2008) 278-289
2. Scott I.U., Loo R.H., Flynn Jr. H.W., and Miller D. Endophthalmitis caused by Enterococcus faecalis: antibiotic selection and treatment outcomes. Ophthalmology 110 (2003) 1573-1577
3. The Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 122 (1996) 830-846
4. Hara J. Relation between causative organism and inflammation onset in pseudophakic endophthalmitis following cataract surgery. Atarashii Ganka 20 (2003) 657-660 [in Japanese]
5. Ariyasu R.G., Nakamura T., Trousdale M.D., and Smith R.E. Intraoperative bacterial contamination of the aqueous humor. Ophthalmic Surg 24 (1993) 367-374
6. Mistlberger A., Ruckhofer J., Raithel E., Müller M., Alzner E., Egger S.F., et al. Anterior chamber contamination during cataract surgery with intraocular lens implantation. J Cataract Refract Surg 23 (1997) 1064-1069
7. Hershberger E., and Rybak M.J. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 44 (2000) 598-601
8. Nakashima M., Uematsu T., Kosuge K., Kusajima H., Ooie T., Masuda Y., et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 39 (1995) 2635-2640
9. Uno T., Hatano H., and Ohashi Y. Antibacterial activity of gatifloxacin against ocular clinical isolates. Atarashii Ganka 21 (2004) 1547-1553 [in Japanese]
10. Löwdin E., Odenholt I., Bengtsson S., and Cars O. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob Agents Chemother 40 (1996) 2478-2482
11. Firsov A.A., Vostrov S.N., Shevchenko A.A., and Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 41 (1997) 1281-1287
12. Kamalarajah S., Silvestri G., Sharma N., Khan A., Foot B., Ling R., et al. Surveillance of endophthalmitis following cataract surgery in the UK. Eye 18 (2004) 580-587
13. Miller J.J., Scott I.U., Flynn Jr. H.W., Smiddy W.E., Newton J., and Miller D. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 139 (2005) 983-987
14. Oshika T., Hatano H., Kuwayama Y., Ogura Y., Ohashi Y., Oki K., et al. Incidence of endophthalmitis after cataract surgery in Japan. Acta Ophthalmol Scand 85 (2007) 848-851
15. Patwardhan A., Rao G.P., Saha K., and Craig E.A. Incidence and outcomes evaluation of endophthalmitis management after phacoemulsification and 3-piece silicone intraocular lens implantation over 6 years in a single eye unit. J Cataract Refract Surg 32 (2006) 1018-1021
16. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46 (2000) 669-683
17. Lister P.D. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 46 (2002) 69-74
18. MacGowan A.P., Rogers C., Holt H.A., Wootton M., and Bowker K.E. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 45 (2001) 2916-2921
19. Blaser J., Stone B.B., Groner M.C., and Zinner S.H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31 (1987) 1054-1060
20. Karlowsky J.A., Zhanel G.G., Davidson R.J., Zieroth S.R., and Hoban D.J. In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth. Antimicrob Agents Chemother 37 (1993) 1154-1157
21. Lister P.D., and Sanders C.C. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 43 (1999) 1118-1123
22. Firsov A.A., Vostrov S.N., Lubenko I.Y., Drlica K., Portnoy Y.A., and Zinner S.H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 1604-1613
23. Zinner S.H., Lubenkol I.Y., Gilbert D., Simmons K., Zhao X., Drlica K., et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52 (2003) 616-622
24. Hosaka M., Yasue T., Fukuda H., Tomizawa H., Aoyama H., and Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 36 (1992) 2108-2117
25. Mather R., Karenchak L.M., Romanowski E.G., and Kowalski R.P. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 (2002) 463-466
26. Wakabayashi E., and Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 38 (1994) 594-601